Search details
1.
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
Mol Carcinog
; 2024 May 02.
Article
in English
| MEDLINE | ID: mdl-38695604
2.
Efficacy of different 8 h time-restricted eating schedules on visceral adipose tissue and cardiometabolic health: A study protocol.
Nutr Metab Cardiovasc Dis
; 34(1): 177-187, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37949715
3.
Integrated variant allele frequency analysis pipeline and R package: easyVAF.
Mol Carcinog
; 62(12): 1877-1887, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37606183
4.
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
Invest New Drugs
; 41(1): 25-34, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36331676
5.
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
Invest New Drugs
; 41(2): 284-295, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36867316
6.
Generation of functional human thymic cells from induced pluripotent stem cells.
J Allergy Clin Immunol
; 149(2): 767-781.e6, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34331993
7.
Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity.
Mol Carcinog
; 61(7): 664-676, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35417043
8.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.
J Natl Compr Canc Netw
; 20(3): 224-234, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35276673
9.
Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205).
Oncologist
; 25(1): e53-e59, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31227647
10.
The humanized mouse: Emerging translational potential.
Mol Carcinog
; 59(7): 830-838, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32275343
11.
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(7): 873-898, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32634781
12.
FYCO1 regulates accumulation of post-mitotic midbodies by mediating LC3-dependent midbody degradation.
J Cell Sci
; 130(23): 4051-4062, 2017 Dec 01.
Article
in English
| MEDLINE | ID: mdl-29196475
13.
Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions.
Mol Carcinog
; 58(3): 398-410, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30378175
14.
Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas.
Mol Carcinog
; 58(5): 666-673, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30575147
15.
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Invest New Drugs
; 37(3): 461-472, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30229512
16.
Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer.
Mol Carcinog
; 57(11): 1651-1663, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30129680
17.
Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
Ann Surg Oncol
; 25(3): 768-775, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-28887726
18.
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.
J Natl Compr Canc Netw
; 16(5): 479-490, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29752322
19.
Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors.
Mol Carcinog
; 56(3): 1189-1196, 2017 03.
Article
in English
| MEDLINE | ID: mdl-27649287
20.
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
Invest New Drugs
; 35(4): 471-477, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28105566